2019


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-β2b for resected high-risk melanoma. J Clin Oncol 37[Suppl; abstr 9504]. 2019.

2018


• Mohammadabadi MD, Hay AE, Shepherd LE, Crump M, Chen BE, Baetz T. Prognostic


- Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker


2017


2016


• Kang A, Hupp M, Ho D, Huang J, Leitzel K, Ali S, Shepherd L, Parulekar WR, Ellis CE,


- Needham J, Nomikos D, Stanton H. Integrating Patient/Public Involvement in the


2015

• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].
- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)]. 2015.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

abstr 504]. 2014.


- Wong R, Au H-J, Ding K, Harvey JA, Stephens S, O'Callaghan CJ, Kneebone A, Ngan

2013


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


2012


Ding K, O'Callaghan C. A phase II study of accelerated hypofractionated 3-dimensional conformal radiotherapy for inoperable T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. Canadian Assoc Rad Oncol [abstr 171], 2012.


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


1036], 2012.

- Ringash J, Au H-J, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland
  AH, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan SS, Easaw JC, Shannon JA,
  El-Tahche F, Walters IB, Tu D, O'Callaghan CJ. Quality of life (QoL) assessment in
  patients (pts) with K-RAS wild-type (WT) chemotherapy refractory metastatic colorectal
  cancer (mCRC) treated with cetuximab (CET) plus brivanib alaninate (BRIV) or placebo:
  Results of the NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl
  4; abstr 542]. 2012.

- Sgroi D, Goss PE, Chapman J-AW, Richardson E, Binns SN, Zhang Y, Schnabel C,
  Erlander MG, Pritchard KL, Han L, Shepherd LE, Pollak MN. Assessment of the
  prognostic and predictive utility of the breast cancer index (BCI): A NCIC CTG MA.14

- Shepherd FA, Bourredjem A, Brambilla E, Domerg C, Douillard J-Y, Filipits M, Graziano
  Soria J-C, Taron M, Tsao MS. Prognostic and predictive effects of KRAS mutation
  subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.
  J Clin Oncol 30[suppl, abstr 7007], 2012.

  osteoporosis in postmenopausal breast cancer patients randomized to adjuvant

- Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore
  Magoski NM, Haydon A, Walters I, Tu D, O'Callaghan CJ, on behalf of NCIC CTG and
  AGITG. Final Analysis of the Phase III randomized trial of cetuximab (CET) + either
  brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-
  RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials

- Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore
  Magoski NM, Haydon AM, Walters IB, Tu D, O'Callaghan CJ. Phase III randomized trial of
  cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with
  metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma
  (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl 4,
  abstr 386], 2012.

- Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L,
  Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term
  Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative
  Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European
  Multidisciplinary Colorectal Cancer Congress, 2012.

- Vogl SE, Altwairgi AK, Chapman J-AW, Zhu L, Shepherd LE, Goss PE. Characterization
  of patients who received further adjuvant endocrine therapy after 5 years of aromatase

- Waldron JN, Parulekar W, OSullivan B, Chen BE, Montenegro A, Nabi A, Winquist E,
  Shenouda G, Siu LL. A phase III study of standard fractionation radiotherapy with
  concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with
  panitumumab in patients with locally advanced stage III and IV squamous cell
  carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). J Clin
  Oncol 30[suppl, abstr TPS5600], 2012.


Clemons M. How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. Cancer Res 71[24, Suppl 3, abstr P2-12-23], 114s, 2011.


• Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model
based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole. Cancer Res 71[24 Suppl 3, abstr S6-2], 114s, 2011.


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


• Soulieres D, Fortin B, Winquist E, Charpentier D, Harnett E, Walsh W, Parulekar W. HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN. J Clin Oncol 28[15s, abstr 5562], 2010.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2009

- Chen B, Graubard B, Flegal K, Gail M. Evaluating strategies to estimate the association
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


• Ding K, Shepherd FA, Tsao MS, Le Maître A, Seymour L. P53 IHC protein expression and tumor size predict survival benefit from adjuvant chemotherapy in stage IB non small cell lung cancer patients. BIT’s 2nd Annual World Cancer Congress, 2009.


• Goodwin RA, Seymour L, Ding K, Gauthier I, Le Maître A, Frymire E, Arnold A, Shepherd FA, Goss GD, Laurie SA. Hypertension in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


• Tsao M-S, Sakurada A, Aviel-Ronen S, Ding K, Liu N, Gandara DR, Johnson DH, Rigas


2008


• Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth
factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


- Verleye L, Coens C, Amant F, van der Burg MEL, Johnson N, Verheijen R, Coronado P,


2007


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Chapman J, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Moase S, Johnston D, Richardson H. Efforts don't end with recruitment: retention


- Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Whitehead M, Seymour L, Winton T, Shepherd FA. P53 protein over-expression but not p53 gene mutation is a poor

- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.

2006

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Ingle J, Tu D, Shepherd L, Palmer M, Pater J, Goss P. NCIC CTG MA.17: Intent to treat...
analysis of randomized patients after a median follow-up of 54 months. 


- O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KI. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


2006.


2005

- Chapman J, Yu E, Royce M, Tai P. Effects of statistical method of assessment on


- Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

- Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.

- Luk C, Ding K, Belch AR, Browman GP, Shustik C, Djurfeldt M, Johnston D, Shepherd LE, Meyer RM. Outcomes of previously untreated older patients with multiple myeloma
over time: An analysis of 3 consecutive trials conducted by the NCIC CTG, 1983-2003. 


- Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

2004

- Chi K.N., Eisenhauer E, Fazli L, Jones T, Powers J, Ayers D, Goldenberg L, Gleave ME.


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


- Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D,


• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn M, Brandes AA,


---

2003


- Paul N, Pater J, Wainman N, Marlin S, Sadura A. Description of adverse effects in


2002


Siu L, Batist G, Bangash N, MacLean M, McIntosh L, Miller WH, Oza A, Petrenicu O, Seymour L. A phase I and pharmacokinetic study of BAY 38-3441 in a daily times five
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2001


Hirte HW, Vergote IB, Jeffrey JR, Grimshaw RN, Stuart GC, Mendiola C, Vorobiof DA,


- Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Marks L, Cirrincione C, Hurd


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2000


Palmer M, Broekhoven M, Garrah A, Tu D. CTASSIST: A computer program for patient


- Williams T, Pentz L, Bacon M, Mak M, Cleary J, Bishop C, Pieters-Mohammed B, Sears


1999


- O’Sullivan B, Davis A, Canadian Sarcoma Group, Sadura A, James K, Zee B. Effect on
radiotherapy field sizes in a recently completed Canadian Sarcoma Group and NCI Canada Clinical Trials Group randomized trial comparing pre-operative and post-operative radiotherapy in extremity soft tissue sarcoma. Am Soc Therapeutic Rad Oncol, 1999.


1998

- Arbuck SG, Ivy P, Setser AN, Eisenhauer E, Wanders J. Common Toxicity Criteria


- Payne D, Shepherd F, Johnston M, Burkes R, Murray N, Deslauriers J, Laberge F,


- van Glabbeke M, Vermorken J, Eisenhauer E. Predictors of survival and time to progression following second- or third-line treatment in advanced ovarian cancer: an analysis of 744 patients treated with paclitaxel, docetaxel or high dose epirubicin.
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1996


- Levine M, Myles J, Shepherd L, El Kum N. Optimal timing of breast cancer surgery

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


---

1995


• Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.
• Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.
• Osoba D, Aaronson N, Zee b. teVelde A, Sprangers M. Modification of the EORTC QLQ-C30 based on reliability testing in large samples of patients with cancer. Quality of Life Research 4(5), 468, 1995.


1994


• Myles J. Design issues of a pilot study to determine equivalent toxicity with G-CSF support. Clinical Trials in Oncology, 1993.


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.
1991

Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1990

- Moertel CG, Loprinzi CL, Witzig TE, Wieand H, Gonchoroff NJ, Reiman HM, Galandiuk


1989


- Eisenhauer E, Evans W, Blackstein M. New agent testing in untreated patients with extensive small cell lung cancer: the NCI Canada experience. NCI-EORTC Symposium
on New Drugs in Cancer Therapy, 1989.


- Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988


- Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Rapp E. Combination chemotherapy for advanced non-small lung cancer -- effective but at what cost? Lung Cancer 4 (suppl),
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1987


1986


O'Dwyer P, Eisenhauer E, Hoth D. Deoxycoformycin in lymphoid malignancies, an overview. NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1986.


Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.


Feld R, Evans WK, Coy P, Hodson I, MacDonald AS, Osoba D, Payne DG, Pater JL.


1984


- Willan A, Pater J. Using baseline measurements to eliminate carryover in the two-period


1983


1981